antikor.co.uk Report : Visit Site

Technical data of the antikor.co.uk

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host antikor.co.uk. Currently, hosted in United Kingdom and its service provider is Sub 6 Limited .

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

home technology antibody drug conjugates targeting platform - ‘optilinked’ fdcs additional products & applications commercial investment and funding partner opportunities antikor business news / media press releases -- in the news scientific publications about us -- about us board of directors management and r&d scientific advisory board contact us press releases -- address & contact careers antibody fragment drug conjugates antibody drug conjugates ( adcs ) are the next generation of antibody therapeutics allowing the specific tumour delivery of potent cytoxic payloads. these whole monoclonal antibody-based products have intrinsic failings which result in a narrow therapeutic index. antikor's unique optilink™ platform enables fragment drug conjugates (fdcs) which provides a simple solution to widen the therapeutic window and so give clinicians more flexibility in treating aggressive solid tumours. read more targeting platform 'optilinked' fdcs with its revolutionary and proprietary optilink tm technology platform, antikor has adopted a novel approach using much smaller antibody fragments ( fdcs ) which have uniquely high payload loadings and penetrate tumours more rapidly, so proving more efficacious, but which clear rapidly from normal tissues , so reducing side-effects. thus, antikor's fdcs have a much wider therapeutic window than conventional adcs and could revolutionise the way we treat solid tumours. read more discovery engine and products antikor’s proprietary antibody fragment frameworks, optimised for maximal dar and fdc manufacturing properties, can be used to discover novel fdcs to any given target. this makes the antikor fdc discovery engine a valuable asset in its own right and the source of future, exciting new products . read more we're attending... antikor ceo/cso presenting at cancer conferences annual meeting, cyprus, june 2018 - visit website 18 jun 18 antikor ceo/cso is speaker at antibody engineering & therapeutics europe, amsterdam, june 2018 - visit website 05 jun 18 antikor’s chairman and ceo/coo handpicked to present at envestor’s investment meeting, london - visit website 25 jan 18 antikor cso/coo invited presentation at pegs boston april 2018 - visit website 30 apr 18 antikor cso to present new tox data at pegs europe, lisbon, 13-14 november 2017 - visit website 13 nov 17 a brief history antikor ltd is a newly established company that is exploiting a novel technology platform called optilinked-fdcs, to generate revolutionary products to treat solid cancers. we are a multidisciplinary spin-out from imperial college london uk now based at the stevenage bioscience catalyst. the company has over 15 years of pioneering experience in the area of small-format, antibody fragment drug conjugates, and has generated product candidates with optimal pharmacokinetics, pharmacodynamics and other encouraging preclinical data. read more current news antikor takes aim at solid tumours with antibody-fragment conjugates superior toxicology data from antikor’s fdc platform february 2017: antikor is seeking to recruit top protein scientists superior toxicology data from antikor’s fdc platform antikor to present at the world adc summit, san diego, usa antikor to present at the european partnering and investment conference, london, uk. partnering opportunities antikor is looking for commercial partners with existing or future interests in the adc space, particulary oncology. we can offer a range of flexible models for collaboration where each party adds value to each other's technology are you seeking :- the solution to increasing the therapeutic index for your adc product? a technology platform with multiple product opportunities, especially in solid tumours? more effective and safer drugs? do you have:- antibodies (or adcs) for which you want to extend their application / patent life? cytotoxic drugs that you want to deliver more efficiently? if the answer to any of these questions is yes, then please contact us to initiate a collaboration and licensing dialogue on antikor's optilink technology platform superior toxicology data from antikor’s fdc platform 27 jun 17 antikor to present at the world adc summit, san diego, usa 15 oct 14 antikor to present at the european partnering and investment conference, london, uk. 01 oct 14 view all -- scientific publications review published for special adc issue of ‘antibodies’ view all useful links about us contact vacancies

URL analysis for antikor.co.uk

http://www.antikor.co.uk/technology/targeting-platform-optilink
http://www.antikor.co.uk/news/antikors-latest-toxicology-data-demonstrates-superior-tolerability-for-its
http://www.antikor.co.uk/about
http://www.antikor.co.uk/technology/additional-products-applications
http://www.antikor.co.uk///contact
http://www.antikor.co.uk/press/antikor-to-present-at-the-european-partnering-and-investment-conference-lon
http://www.antikor.co.uk/technology
http://www.antikor.co.uk/news/antikor-takes-aim-at-solid-tumours-with-antibody-fragment-conjugates
http://www.antikor.co.uk/news
http://www.antikor.co.uk/vacancies
http://www.antikor.co.uk/investors/antikor-business
http://www.antikor.co.uk/publications/review-published-for-special-adc-issue-of-antibodies
http://www.antikor.co.uk/press/antikors-latest-toxicology-data-demonstrates-superior-tolerability-for-its
http://www.antikor.co.uk/
http://www.antikor.co.uk/management

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Error for "antikor.co.uk".

the WHOIS query quota for 2600:3c03:0000:0000:f03c:91ff:feae:779d has been exceeded
and will be replenished in 70 seconds

WHOIS lookup made at 16:56:18 01-Oct-2017

--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:

Copyright Nominet UK 1996 - 2017.

You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REFERRER http://www.nominet.org.uk

  REGISTRAR Nominet UK

SERVERS

  SERVER co.uk.whois-servers.net

  ARGS antikor.co.uk

  PORT 43

  TYPE domain

DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2017.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REGISTERED no

DOMAIN

  NAME antikor.co.uk

NSERVER

  DNS.US-NOC.COM 205.234.110.53

  DNS.UK-NOC.COM 83.223.98.50

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .